Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ZFZiyu FengJCJia ChenHDHaiping Dai

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals venetoclax plus hypomethylating agent is effective in CBFβ::MYH11(+) AML, suggesting a safer alternative to traditional treatment.

Key Points

  • This study aims to evaluate the efficacy of venetoclax combined with a hypomethylating agent as induction therapy in CBFβ::MYH11(+) AML patients compared to standard treatment.
  • Conducted a retrospective analysis on 81 newly diagnosed CBFβ::MYH11(+) AML patients
  • Patients received either venetoclax plus hypomethylating agent or standard 7+3 regimen
  • Measured treatment response through MRD and complete molecular remission after induction and consolidation therapy.
  • Both treatment groups achieved similar complete remission rates of 96.3%
  • Venetoclax plus hypomethylating agent group showed fewer treatment-related adverse events
  • The 2-year relapse-free survival probabilities were 66% for venetoclax group and 53.2% for the 7+3 group.

Cite This Study

Feng et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3c0https://doi.org/10.1182/blood-2025-1674
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax combined with hypomethylating agents for favorable risk acute myeloid leukemia: A single center experience.2024 · 1 citations
  2. 2Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  3. 3Venetoclax in the treatment of acute myeloid leukemia: Beyond <scp>VIALE‐A</scp>2024 · 3 citations
  4. 4Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML2025 · 3 citations
  5. 5Determinants of survival in 356 patients failing frontline HMA-Ven for newly-diagnosed AML.2026